Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET
Company Participants
Rob Barrow – Chief Executive Officer
Schond Greenway – Chief Financial Officer
Dan Karlin – Chief Medical Officer
Conference Call Participants
Charles Duncan – Cantor Fitzgerald
Brian Abrahams – RBC Capital Markets
Francois Brisebois – Oppenheimer
Elemer Piros – EF Hutton
Patrick Trucchio – H.C. Wainwright
Operator
Good afternoon, and welcome to the Mind Medicine First Quarter 2023 Financial Results and Corporate Update Conference call. Currently, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co and a recording will be available after the call.
For opening remarks, I would like to introduce Rob Barrow, CEO of MindMed. Please go ahead.
Rob Barrow
Thank you and good afternoon, everyone. Welcome to our first quarter 2023 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of MindMed's website and our quarterly report on Form 10-Q for the quarter ended March 31, 2023, will be filed today with the Securities and Exchange Commission.
Joining me today is Schond Greenway, our Chief Financial Officer; Dr. Dan Karlin, our Chief Medical Officer; and Dr. Miri Halperin Wernli, our Executive President.
During today's call, we'll be making certain forward-looking statements including without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks such as changes in market conditions, difficulties associated with research and development and regulatory approval processes that are described in the filings made with the SEC, including the most recent annual report on Form 10-K and quarterly report on Form 10-Q.
Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC or other significant events occurring outside of MindMed's normal course of business. You are caution not to place undue reliance on these forward-looking statements which are made as of today, May 4, 2023.
MindMed disclaims any obligation to update such statements, even if management's views change, except as required by law. I would like to begin by reiterating our deep commitment to advancing our organization and delivering new life-changing treatment options to the many individuals living with brain health disorders. As we pursue our strategy to bring our lead product candidates to market, we believe we are laying the foundation to create lasting value for our shareholders.